India’s Pharma Exports Reach $5 Billion In April-May, Reports Pharmexcil

India’s pharmaceutical exports achieved $4.9 billion during April-May FY26, according to the Pharmaceuticals Export Promotion Council (Pharmexcil).

This reflects a solid 7.38% growth compared to the same period last year, indicating strong global demand for Indian medicines.

Pharmexcil attributed the growth to sustainable manufacturing, global market expansion, and faster adoption of digital regulatory processes.

These initiatives directly support India’s larger vision of reaching a trillion-dollar pharmaceutical trade target in the coming years.

Namit Joshi, Chairman of Pharmexcil, said drug formulations and biologicals continue to lead exports with consistent year-on-year growth.

Joshi emphasised that global demand, technological advancements, regulatory ease, and economic stability drive this impressive export performance.

Formulations and biologicals made up 75.74% of the total exports, remaining the sector’s core strength during this period.

Bulk drugs and intermediates also grew by 4.4% in May, contributing significantly to the overall export performance.

Vaccine exports showed remarkable growth of 13.64%, reaching $190.13 million, highlighting India’s critical role in global healthcare.

Surgical items rose by 8.58%, while Ayush and herbal products grew by 7.36%, reflecting rising international demand for diversified offerings.

The US remained the largest export destination with $1.7 billion, accounting for 34.5% of India’s total pharmaceutical exports.

Regions like NAFTA, Europe, Africa, and Latin America together accounted for 76% of total export volumes.

Emerging markets such as ASEAN displayed promising growth, indicating India’s successful efforts at diversifying export destinations.

Joshi noted that India-UK Free Trade Agreement discussions could further strengthen supply chains and attract foreign investments.

Pharmexcil expects that global partnerships, contract manufacturing, and joint research will continue boosting India’s pharmaceutical growth momentum.

Also read: GIFT City Emerges As Investment Magnet Despite Complex Rules For Family Offices